{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:38:20Z","timestamp":1776861500952,"version":"3.51.2"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canlet.2026.218383","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:45:11Z","timestamp":1772178311000},"page":"218383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma"],"prefix":"10.1016","volume":"646","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-5467","authenticated-orcid":false,"given":"Mahnaz","family":"Norouzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4356-9718","authenticated-orcid":false,"given":"Subin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Somers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-2638","authenticated-orcid":false,"given":"Eddy Shih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Mark Evers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2557-5719","authenticated-orcid":false,"given":"Eric J.","family":"Rellinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-9122","authenticated-orcid":false,"given":"Piotr","family":"Rychahou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218383_bib1","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/EDBK_349783","article-title":"High-risk and relapsed neuroblastoma: toward more cures and better outcomes","volume":"42","author":"DuBois","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.canlet.2026.218383_bib2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/children10081302","article-title":"Treatment of high-risk neuroblastoma","volume":"10","author":"Krystal","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.canlet.2026.218383_bib3","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.3390\/ijms24108470","article-title":"Biological insight and recent advancement in the treatment of neuroblastoma","volume":"24","author":"Rivera","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218383_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/jcm12030754","article-title":"Long-term survival of neuroblastoma patients receiving surgery, chemotherapy, and radiotherapy: a propensity score matching study","volume":"12","author":"Li","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218383_bib5","article-title":"Therapy resistance in neuroblastoma: mechanisms and reversal strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218383_bib6","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.3390\/cancers14184421","article-title":"MYCN impact on high-risk neuroblastoma: from diagnosis and prognosis to targeted treatment","volume":"14","author":"Bartolucci","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218383_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/children5080107","article-title":"Late effects and survivorship issues in patients with neuroblastoma","volume":"5","author":"Friedman","year":"2018","journal-title":"Children"},{"key":"10.1016\/j.canlet.2026.218383_bib8","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218383_bib9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/bjc.2016.302","article-title":"Factors associated with recurrence and survival length following relapse in patients with neuroblastoma","volume":"115","author":"Basta","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218383_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4972410","article-title":"Neuroblastoma cell lines are refractory to genotoxic drug\u2010mediated induction of ligands for NK cell\u2010activating receptors","volume":"2018","author":"Veneziani","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218383_bib11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/cancers14030627","article-title":"Chemotherapy side-effects: not all DNA damage is equal","volume":"14","author":"van den Boogaard","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218383_bib12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/PPO.0000000000000561","article-title":"DNA damage repair inhibitors\u2014combination therapies","volume":"27","author":"Smith","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.canlet.2026.218383_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.629266","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218383_bib14","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3389\/fonc.2019.01388","article-title":"Harnessing DNA double-strand break repair for cancer treatment","volume":"9","author":"Trenner","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218383_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fonc.2020.00371","article-title":"Targeting the DNA damage response for the treatment of high risk neuroblastoma","volume":"10","author":"Southgate","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218383_bib16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/hed.24562","article-title":"DNA-Pk(CS) expression in oropharyngeal squamous cell carcinoma: correlations with human papillomavirus status and recurrence after transoral robotic surgery","volume":"39","author":"Weaver","year":"2017","journal-title":"Head Neck"},{"key":"10.1016\/j.canlet.2026.218383_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145744","article-title":"DNA-dependent protein kinase as molecular target for radiosensitization of neuroblastoma cells","volume":"10","author":"Dolman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218383_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218383_bib19","first-page":"837","article-title":"Targeting DNA repair pathways to overcome cancer drug resistance","volume":"4","author":"van Waardenburg","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.canlet.2026.218383_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218383_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1133472","article-title":"Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: clinical outcomes and mechanistic insights","volume":"11","author":"Ragupathi","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2026.218383_bib22","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1016\/j.apsb.2021.07.029","article-title":"DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218383_bib23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3389\/fgene.2020.01036","article-title":"Combining PARP and DNA-PK inhibitors with irradiation inhibits HPV-negative head and neck cancer squamous carcinoma growth","volume":"11","author":"Zeng","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.canlet.2026.218383_bib24","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1541-7786.MCR-21-0612","article-title":"DNA-PK inhibitor peposertib amplifies radiation-induced inflammatory micronucleation and enhances TGF\u03b2\/PD-L1 targeted cancer immunotherapy","volume":"20","author":"Carr","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218383_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218383_bib26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1535-7163.MCT-23-0552","article-title":"Differential distribution of the DNA-PKcs inhibitor peposertib selectively radiosensitizes patient-derived melanoma brain metastasis xenografts","volume":"23","author":"Ji","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218383_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114109","article-title":"Recent advances in DDR (DNA damage response) inhibitors for cancer therapy","volume":"230","author":"Cheng","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2026.218383_bib28","doi-asserted-by":"crossref","first-page":"6684","DOI":"10.3390\/ijms21186684","article-title":"Inhibition of DNA repair in cancer therapy: toward a multi-target approach","volume":"21","author":"Lodovichi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218383_bib29","article-title":"DNA repair and replicative stress addiction in neuroblastoma","volume":"4","author":"Durinck","year":"2024","journal-title":"EJC Paediatr. Oncol."},{"key":"10.1016\/j.canlet.2026.218383_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41467-019-13817-8","article-title":"Integrative discovery of treatments for high-risk neuroblastoma","volume":"11","author":"Almstedt","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218383_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2529","article-title":"The genetic landscape of high-risk neuroblastoma","volume":"45","author":"Pugh","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2026.218383_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/35056049","article-title":"Chromosomal stability and the DNA double-stranded break connection","volume":"2","author":"Van Gent","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2026.218383_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-4165(98)00020-8","article-title":"Increased expression of DNA-dependent protein kinase confers resistance to adriamycin","volume":"1381","author":"Shen","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2026.218383_bib34","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/1535-7163.MCT-11-0535","article-title":"Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K","volume":"11","author":"Munck","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218383_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/cancers10120487","article-title":"Role of BRCA mutations in cancer treatment with poly (ADP-ribose) polymerase (PARP) inhibitors","volume":"10","author":"Faraoni","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218383_bib36","first-page":"22","article-title":"Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment","volume":"1","author":"Hsu","year":"2012","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218383_bib37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fonc.2019.00635","article-title":"DNA-PK as an emerging therapeutic target in cancer","volume":"9","author":"Mohiuddin","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218383_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1172\/JCI127483","article-title":"Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy","volume":"130","author":"Willoughby","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218383_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11033-019-05105-x","article-title":"Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells","volume":"47","author":"Kopa","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.canlet.2026.218383_bib40","article-title":"DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a cost","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218383_bib41","doi-asserted-by":"crossref","first-page":"7332","DOI":"10.1038\/s41467-023-43134-0","article-title":"A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218383_bib42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.31053","article-title":"Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression","volume":"142","author":"Rifatbegovic","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218383_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.84","article-title":"Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma","volume":"4","author":"Kocak","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218383_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/11591630-000000000-00000","article-title":"Pharmacologic management of high-risk neuroblastoma in children","volume":"13","author":"Ganeshan","year":"2011","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.canlet.2026.218383_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2019.02.003","article-title":"Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children's Oncology Group (COG)","volume":"112","author":"Pinto","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218383_bib46","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/1533034615597366","article-title":"PI3K inhibitor combined with chemotherapy can enhance the apoptosis of Neuroblastoma cells in vitro and in vivo","volume":"15","author":"Geng","year":"2016","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2026.218383_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190970","article-title":"Doxorubicin-provoked increase of mitotic activity and concomitant drain of G0-pool in therapy-resistant BE (2)-C neuroblastoma","volume":"13","author":"Hultman","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218383_bib48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/CM9.0000000000001234","article-title":"Targeted inhibition of myeloid-derived suppressor cells in the tumor microenvironment by low-dose doxorubicin to improve immune efficacy in murine neuroblastoma","volume":"134","author":"Xu","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.canlet.2026.218383_bib49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s42003-020-01529-5","article-title":"Reciprocal interactions between tumour cell populations enhance growth and reduce radiation sensitivity in prostate cancer","volume":"4","author":"Paczkowski","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2026.218383_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.31053","article-title":"Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression","volume":"142","author":"Rifatbegovic","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218383_bib51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nature10910","article-title":"Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes","volume":"483","author":"Molenaar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218383_bib52","volume":"vol. 2","author":"Matthay","year":"2016"},{"key":"10.1016\/j.canlet.2026.218383_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-med-011514-023121","article-title":"Neuroblastoma: molecular pathogenesis and therapy","volume":"66","author":"Louis","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.canlet.2026.218383_bib54","doi-asserted-by":"crossref","first-page":"djx062","DOI":"10.1093\/jnci\/djx062","article-title":"Loss of DNA damage response in neuroblastoma and utility of a PARP inhibitor","volume":"109","author":"Takagi","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218383_bib55","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1038\/s41388-021-02018-7","article-title":"Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes","volume":"40","author":"Lebedev","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218383_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108171","article-title":"11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma","volume":"32","author":"Siaw","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218383_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.929123","article-title":"Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma","volume":"12","author":"Keller","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218383_bib58","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-020-18987-4","article-title":"Pan-neuroblastoma analysis reveals age-and signature-associated driver alterations","volume":"11","author":"Brady","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218383_bib59","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/cancers15030560","article-title":"Therapeutic targeting of ALK in neuroblastoma: experience of Italian precision medicine in pediatric oncology","volume":"15","author":"Pastorino","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218383_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072182","article-title":"Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis","volume":"8","author":"Boeva","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218383_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.semcdb.2021.02.001","article-title":"Chromothripsis, DNA repair and checkpoints defects","volume":"123","author":"Simovic","year":"2022","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2026.218383_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-020-00553-6","article-title":"Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival","volume":"18","author":"Keane","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2026.218383_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neo.2020.11.001","article-title":"Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes","volume":"23","author":"Fern\u00e1ndez-Blanco","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2026.218383_bib64","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22495","article-title":"Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis","volume":"8","author":"Uryu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218383_bib65","article-title":"Mutational topography reflects clinical neuroblastoma heterogeneity","volume":"3","author":"Rodriguez-Fos","year":"2023","journal-title":"Cell Genom."},{"key":"10.1016\/j.canlet.2026.218383_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115537","article-title":"DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition","volume":"44","author":"Hayes","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218383_bib67","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1158\/1078-0432.CCR-17-0593","article-title":"Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition","volume":"23","author":"Sanmart\u00edn","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218383_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28061","article-title":"Neuroblastoma stage 4S: tumor regression rate and risk factors of progressive disease","volume":"67","author":"Tas","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2026.218383_bib69","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","article-title":"Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors","volume":"9","author":"Hanker","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218383_bib70","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/cells10051261","article-title":"PI3K\/mTOR dual inhibitor PF-04691502 is a schedule-dependent radiosensitizer for gastroenteropancreatic neuroendocrine tumors","volume":"10","author":"Chow","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218383_bib71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/01.sla.0000220040.66012.a9","article-title":"Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma","volume":"243","author":"Rychahou","year":"2006","journal-title":"Ann. Surg."},{"key":"10.1016\/j.canlet.2026.218383_bib72","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod. Pathol.: Offi. J. United States Canada. Acad. Pathol., Inc"},{"key":"10.1016\/j.canlet.2026.218383_bib73","article-title":"Impact of backscatter material thickness on the depth dose of orthovoltage irradiators for radiobiology research","volume":"64","author":"Chen","year":"2019","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.canlet.2026.218383_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102123","article-title":"Peroxiredoxin IV plays a critical role in cancer cell growth and radioresistance through the activation of the Akt\/GSK3 signaling pathways","volume":"298","author":"Ding","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218383_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.147840","article-title":"Extracellular vesicles released after cranial radiation: an insight into an early mechanism of brain injury","volume":"1782","author":"Sukati","year":"2022","journal-title":"Brain Res."},{"key":"10.1016\/j.canlet.2026.218383_bib76","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218383_bib77","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41588-021-00790-6","article-title":"ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis","volume":"53","author":"Granja","year":"2021","journal-title":"Nat. Genet."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:41:33Z","timestamp":1776858093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526001461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":77,"alternative-id":["S0304383526001461"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218383","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218383"}}